<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Suppressor T cells are one of the determinants of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) clinical outcome </plain></SENT>
<SENT sid="1" pm="."><plain>LAP(+)CD4(+) T cell is a recently identified subset of suppressor T cells </plain></SENT>
<SENT sid="2" pm="."><plain>This study was designed to investigate their clinical relevance in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: Sixty patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and 24 healthy donors (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) were enrolled in this study </plain></SENT>
<SENT sid="4" pm="."><plain>The percentages of LAP(+)CD4(+) T cells in peripheral blood and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue were measured </plain></SENT>
<SENT sid="5" pm="."><plain>The phenotype and functional relevance of LAP(+)CD4(+) T cells were analyzed subsequently </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The percentages of LAP(+)CD4(+) T cells in peripheral blood of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were significantly higher than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> vs. <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>: 3.1% ± 0.78% vs. 8.8% ± 5.8%, P &lt; 0.0001) and in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue when compared with nontumor tissue (nontumor vs. <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>: 3.2% ± 1.1% vs. 9.5% ± 5.5%, P = 0.0002) </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, LAP(+)CD4(+) T cells with effector memory (EM) phenotype were more likely to accumulate in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> sites than in peripheral blood </plain></SENT>
<SENT sid="8" pm="."><plain>These LAP(+)CD4(+) T cells produced significantly higher levels of IFN-γ, IL-17 and comparatively lower IL-2 and very few IL-10 </plain></SENT>
<SENT sid="9" pm="."><plain>LAP(+)CD4(+) T cells could suppress the proliferation of LAP(-)CD4(+) T cells that were partially mediated by TGF-β </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, these LAP(+)CD4(+) T cells accumulated in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site and increased further in the peripheral blood in patients with <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: LAP(+)CD4(+) T cells as a suppressor subset could accumulate in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment and circulated more in the peripheral blood with <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>